文献速递免疫规划慢病防控与筛查卫生政策与健康促进

科兴新冠疫苗对巴西社会不平等大城市老年人群新冠结局的影响:目标试验模拟研究

Impact of CoronaVac on Covid-19 outcomes of elderly adults in a large and socially unequal Brazilian city: A target trial emulation study.
PubMed 文献 · Vaccine · 2023-08-10

在巴西福塔莱萨市,基于监测与疫苗接种数据构建回顾性队列,将324,302名≥60岁老年人中接种者与未接种者按1:1匹配,评估科兴新冠疫苗对新冠住院、ICU入住和死亡的有效性。第二剂后14天起,对死亡有效性82.3%(95%CI 66.3-93.9),对ICU入住68.4%(95%CI 42.3-86.4),对住院55.8%(95%CI 42.7-68.3)。

要点

  • 科兴新冠疫苗对≥60岁老年人新冠死亡的有效性为82.3%(95%CI 66.3-93.9)。
  • 对ICU入住有效性68.4%(95%CI 42.3-86.4),对住院有效性55.8%(95%CI 42.7-68.3)。
  • 尽管疫苗供应延迟且 efficacy 试验证据有限,科兴新冠疫苗有助于预防老年人新冠死亡和重症。

核心结论

  • 尽管疫苗供应存在关键延迟且 efficacy 试验证据有限,科兴新冠疫苗有助于预防≥60岁老年人新冠死亡和重症。

研究设计与样本

  • 使用巴西福塔莱萨市疫苗接种和监测大型观察数据库,定义回顾性队列,纳入324,302名≥60岁合格老年人。
  • 队列包括2021年1月21日至2021年8月31日接种者,按年龄、性别和居住社区人类发展指数基线协变量1:1匹配未接种者。

主要发现

  • 获得62,643对匹配数据评估两剂科兴新冠疫苗方案有效性,匹配人群人口学特征对福塔莱萨市人口具有统计学代表性。
  • 以累积发病率作为各组风险,自第二剂接种后第14天起,对新冠相关死亡有效性82.3%(95%CI 66.3-93.9)。
  • 对ICU入住有效性68.4%(95%CI 42.3-86.4),对住院有效性55.8%(95%CI 42.7-68.3)。

关键数值与推荐

  • 分析仅纳入新冠相关严重结局:住院、ICU入住和死亡。
  • 每种结局的疫苗有效性通过两组间风险比计算,风险由Kaplan-Meier估计量获得。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although CoronaVac was the only Covid-19 vaccine adopted in the first months of the Brazilian vaccination campaign, randomized clinical trials to evaluate its efficacy in elderly adults were limited. In this study, we use routinely collected surveillance and SARS-CoV-2 vaccination and testing data comprising the population of the fifth largest city of Brazil to evaluate the effectiveness of CoronaVac in adults 60+ years old against severe outcomes. METHODS: Using large observational databases on vaccination and surveillance data from the city of Fortaleza, Brazil, we defined a retrospective cohort including 324,302 eligible adults aged ≥60 years to evaluate the effectiveness of the CoronaVac vaccine. The cohort included individuals vaccinated between January 21, 2021, and August 31, 2021, who were matched with unvaccinated persons at the time of rollout following a 1:1 ratio according to baseline covariates of age, sex, and Human Development Index of the neighborhood of residence. Only Covid-19-related severe outcomes were included in the analysis: hospitalization, ICU admission, and death. Vaccine effectiveness for each outcome was calculated by using the risk ratio between the two groups, with the risk obtained by the Kaplan-Meier estimator. RESULTS: We obtained 62,643 matched pairs for assessing the effectiveness of the two-dose regimen of CoronaVac. The demographic profile of the matched population was statistically representative of the population of Fortaleza. Using the cumulative incidence as the risk associated with each group, starting at day 14 since the receipt of the second dose, we found an 82.3 % (95 % CI 66.3-93.9) effectiveness against Covid-19-related death, 68.4 % (95 % CI 42.3-86.4) against ICU admission, and 55.8 % (95 % CI 42.7-68.3) against hospital admission. CONCLUSIONS: Our results show that, despite critical delays in vaccine delivery and limited evidence in efficacy trial estimates, CoronaVac contributed to preventing deaths and severe morbidity due to Covid-19 in elderly adults.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Monteiro HS, Lima Neto AS, Kahn R, et al. Impact of CoronaVac on Covid-19 outcomes of elderly adults in a large and socially unequal Brazilian city: A target trial emulation study. Vaccine. 2023. PMID: 37573202. doi:10.1016/j.vaccine.2023.07.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。